Inclusion Criteria:

- Persons with a progranulin gene mutation and at risk of developing FTD symptoms as
evidenced by a biomarker, or persons with a progranulin gene mutation and diagnosed
with FTD.

- If symptomatic, one or more of the criteria for the diagnosis of possible behavioral
variant FTD, or a diagnosis of Primary Progressive Aphasia.

- Study partner who consents to study participation and who cares for/visits the
participant daily for at least 5 hours per week.

- Written informed consent must be obtained and documented (from the participant or,
where jurisdictions allow it, from their legal decision maker).

Exclusion Criteria:

- Dementia due to a condition other than FTD including, but not limited to, Alzheimer's
disease, Parkinson's disease, dementia with Lewy bodies, Huntington disease, or
vascular dementia.

- Known history of severe allergic, anaphylactic, or other hypersensitivity reactions to
chimeric, human, or humanized antibodies or fusion proteins.

- Current uncontrolled hypertension, diabetes mellitus or thyroid disease. Clinically
significant heart disease, liver disease or kidney disease. History or evidence of
clinically significant brain disease other than FTD.

- Females who are pregnant or breastfeeding, or planning to conceive within the study
period.

- Any experimental vaccine or gene therapy.

- History of cancer within the last 5 years.

- Current use of anticoagulant medications (e.g., coumadin, heparinoids, apixaban).

- Residence in a skilled nursing facility, convalescent home, or long term care facility
at screening; or requires continuous nursing care.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 4/2/2024. Questions regarding updates should be directed to the study team contact.